scholarly journals Management of hepatic granulomatous tuberculosis complicating intravesical BCG for superficial bladder cancer

2012 ◽  
Vol 1 (3) ◽  
Author(s):  
Vincent Fradet ◽  
Christiane Gaudreau ◽  
Paul Perrotte ◽  
Jean Côté ◽  
Jean-Marie Paquin
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Granulomatous Hepatitis ◽  
Bacille Calmette Guerin ◽  
Systemic Complications ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Management Alternatives

Intravesical bacille Calmette-Guérin (BCG) therapy is the most effective treatmentfor high-risk superficial bladder cancer. Severe systemic complications are rare, but may occur in approximately 1% of cases. We report a severe complicationof intravesical BCG: a disseminated Mycobacterium bovis infectionwith biopsy-proven granulomatous hepatitis in a patient with bladder cancer. We also elaborate on the different management alternatives.

scholarly journals The Recovery of an intravesical BCG-induced arthritis after RITUXIMAB treatment

2021 ◽  
Author(s):  
Nejla El amri ◽  
Héla Zeglaoui ◽  
Salma Hmila ◽  
dhouha khalifa ◽  
Sadok Lataoui ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Rare Case ◽  
Superficial Bladder Cancer ◽  
Standard Of Care ◽  
Severe Form ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Risk Of Relapse

BCG intra-vesical instillation is the standard of care for superficial bladder cancer at high risk of relapse and progression. Yet, this treatment can cause dysimmune complications. Osteoarticular manifestations related to BCG therapy are rare and frequently mild. We report a rare case of a severe form successfully treated with Rituximab.

Mycobacterium bovis Cerebellar Abscess Following Treatment With Bacillus Calmette-Guérin

2016 ◽  
Vol 30 (3) ◽  
pp. 378-380 ◽  
Author(s):  
Mollie W. Sheron ◽  
Shannon L. Holt ◽  
Christopher W. Ingram
Keyword(s):  
Bladder Cancer ◽  
Mycobacterium Bovis ◽  
Superficial Bladder Cancer ◽  
Altered Mental Status ◽  
Bacillus Calmette Guerin ◽  
Systemic Complications ◽  
Cns Infections ◽  
Antituberculosis Therapy ◽  
Cerebellar Abscess ◽  
Bcg Therapy

Bacillus Calmette-Guérin (BCG) is a live, attenuated strain of Mycobacterium bovis that is used to treat superficial bladder cancer. Although its use is typically associated with only mild, localized side effects, rare systemic complications can occur. Disseminated mycobacterium infections after BCG therapy have been reported in over 30 cases; however, central nervous system (CNS) infections do not commonly occur. We report a 74-year-old male who developed a M. bovis cerebellar abscess after receiving intravesical BCG infusion for bladder cancer for less than 1 year. This patient was successfully treated with antituberculosis therapy and corticosteroids. This patient case demonstrates that early-onset M bovis CNS infections can occur after BCG therapy. Patients presenting with altered mental status while on BCG therapy should be evaluated for disseminated infections.

scholarly journals Mycobacterial Brain Tuberculomas due to Bacille Calmette-Guérin Intravesical Chemotherapy for Bladder Cancer: A Case Report and Literature Review

2011 ◽  
Vol 22 (3) ◽  
pp. 104-106 ◽  
Author(s):  
Vitaly Golub ◽  
Prashant Malhotra ◽  
Shital Patel
Keyword(s):  
Central Nervous System ◽  
Bladder Cancer ◽  
Nervous System ◽  
Superficial Bladder Cancer ◽  
Present Report ◽  
Bacille Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy

Bacille Calmette-Guérin (BCG) immunotherapy is widely used for the treatment of superficial bladder cancer. The authors believe that the present report is one of the first to document cerebral BCG tuberculoma in a 73-year-old immunocompetent man, three years after intra-vesical BCG immunotherapy. His workup revealed no identifiable extracranial source. He responded well to treatment with rifampin, ethambutol and moxifloxacin.Patients undergoing intravesical BCG therapy should be closely monitored for the development of this complication. Prolonged antitubercular therapy, possibly including moxifloxacin, appears to be beneficial in the treatment of central nervous system tuberculous infections.

Granulomatous Hepatitis as a Rare Complication of Intravesical BCG Therapy for Bladder Cancer: Case Report

2010 ◽  
Vol 30 (3) ◽  
pp. 1092-1095
Author(s):  
İbrahim Koral ÖNAL ◽  
Meral AKDOĞAN ◽  
Adalet AYPAK ◽  
Perihan OĞUZ ◽  
Tülay TEMUÇİN KEKLİK ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Case Report ◽  
Rare Complication ◽  
Cancer Case ◽  
Granulomatous Hepatitis ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Bladder Cancer Case ◽  
Intravesical Bcg Therapy

A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. TPS493-TPS493 ◽  
Author(s):  
Noah M. Hahn ◽  
Sam S. Chang ◽  
Maxwell Meng ◽  
Neal D. Shore ◽  
Badrinath R. Konety ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Checkpoint Inhibitors ◽  
Objective Response ◽  
Locally Advanced ◽  
Unmet Need ◽  
Clinical Activity ◽  
Free Survival ◽  
Bcg Therapy ◽  
Intravesical Bcg

TPS493 Background: Immune checkpoint inhibitors, including nivo (anti–PD-1), have demonstrated favorable tolerability and efficacy profiles, ushering in a new treatment (tx) paradigm for advanced bladder cancer (advBC). However, an unmet need exists for new effective tx options in earlier stages of disease, specifically for patients (pts) with BCG-unresponsive, high-risk NMIBC. Increased IDO and PD-L1 expression in NMIBC tumors (Inman, et al. Cancer 2007; Hudolin, et al. Anticancer Res 2017), support the combination of anti–PD-1 and IDO1 inhibition in NMIBC. BMS-986205, a selective, potent, once-daily IDO1 inhibitor that works early in the IDO1 pathway, has demonstrated clinical activity in combination with nivo in pts with immunotherapy-naive advBC who received ≥ 1 prior line of therapy (objective response rate, 37%; Tabernero, et al. J Clin Oncol 2018;36(suppl) [abstr 4512]). These findings provide a rationale for investigation of nivo + BMS-986205 ± intravesical BCG therapy in BCG-unresponsive high-risk NMIBC. Here we describe a phase 2, randomized, open-label study assessing the safety and efficacy of nivo ± BMS-986205 ± intravesical BCG in pts with BCG-unresponsive, high-risk NMIBC. Methods: Pts aged ≥ 18 years with BCG-unresponsive (per February 2018 FDA guidance), high-risk NMIBC, defined as carcinoma-in-situ (CIS) with or without papillary component, any T1, or Ta high-grade lesions, will be enrolled. Pts must have urothelial carcinoma as the predominant histological component (>50%). Key exclusion criteria include locally advanced or metastatic BC, upper urinary tract disease within 2 years, prostatic urethral disease within 1 year, and prior immunotherapy. Using a novel adaptive-type design, pts will be randomized to 1 of 4 tx arms with nivo ± BMS-986205 ± BCG. Primary endpoints include proportion of pts with CIS with complete response (CR), duration of CR in pts with CIS, and event-free survival for all pts without CIS. Secondary endpoints are progression-free survival and safety. This global study in 13 countries is underway, with a target enrollment of 436 pts. ( Clinical trial information: NCT03519256.

Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer

1998 ◽  
Vol 30 (1) ◽  
pp. 41-44 ◽  
Author(s):  
F. Yalçinkaya ◽  
L. Kamiş ◽  
O. Özteke ◽  
B. Günlüsoy ◽  
O. Yiĝitbasi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Superficial Bladder Cancer ◽  
Standard Dose ◽  
Low Doses ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Intravesical Bcg Therapy
Sign in / Sign up

Export Citation Format

Share Document